Patients with Huntington’s disease have a genetic mutation that triggers proteins to misfold and clump together in the brain. These clumps interfere with cell function and eventually lead to cell death. The new treatment leverages peptide-brush polymers, which act as a shield to prevent proteins from binding to one another. In studies in mice, the treatment successfully rescued neurons to reverse symptoms. 

More than 25 payloads sponsored by the International Space Station (ISSInternational Space Station) National Laboratory, including technology demonstrations, in-space manufacturing, student experiments, and multiple projects funded by the U.S. National Science Foundation (NSF), are bound for the orbiting outpost. These investigations, launching on SpaceX’s 31st Commercial Resupply Services (CRS) mission for NASANational Aeronautics and Space Administration, aim to improve life on Earth through space-based research and foster a sustainable economy in low Earth orbit(Abbreviation: LEO) The orbit around the Earth that extends up to an altitude of 2,000 km (1,200 miles) from Earth’s surface. The International Space Station’s orbit is in LEO, at an altitude of approximately 250 miles. (LEO).

A new study led by researchers at Albert Einstein College of Medicine involving more than 200,000 adults found that the COVID-19 pandemic caused a 29% increase in risk for developing dyslipidemia, a condition involving abnormal lipid (fat) levels in the blood. Seniors and people with type 2 diabetes were even more strongly affected, experiencing an approximately two-fold increased risk for developing dyslipidemia, which is a major risk factor for cardiovascular diseases such as heart attack and stroke. The research was published today in the print edition of The Journal of Clinical Investigation.

Pennington Biomedical Research Center researchers are gearing up and preparing to head to San Antonio for ObesityWeek 2024, presented by The Obesity Society. Pennington Biomedical will be well represented at the conference, as faculty members are not just participating in, but leading courses, presentations and speaker panels during the event. 

Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 cutaneous melanoma, according to the results of a single-arm phase 2 clinical trial led by the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute (NCI).